azacitidine
Sign in to saveAlso known as 5-AZAC, 5-azacytidine, ladakamycin, 4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one, 5-AZC
Azacitidine, sold under the brand name Vidaza among others, is a medication used for the treatment of myelodysplastic syndrome, myeloid leukemia, and juvenile myelomonocytic leukemia. It is a chemical analog of cytidine, a nucleoside in DNA and RNA. Azacitidine and its deoxy derivative, decitabine (also known as 5-aza-2′-deoxycytidine) were first synthesized in Czechoslovakia as potential chemotherapeutic agents for cancer.
Research
10,090 papers- Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.The New England journal of medicine · 2022
- Azacitidine.IARC monographs on the evaluation of carcinogenic risks to humans · 1990
- Azacitidine-induced pneumonitis and literature review.BMJ case reports · 2020
- Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
- 5-Azacytidine/Azacitidine.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2010
via PubMed
~8 min read
Encyclopedic overview
8 sectionsContents
- Medical uses
- Mechanism of action
- Inhibition of methylation
- Toxicity
- History
- Research
- References
- External links
Azacitidine, sold under the brand name Vidaza among others, is a medication used for the treatment of myelodysplastic syndrome, myeloid leukemia, and juvenile myelomonocytic leukemia. It is a chemical analog of cytidine, a nucleoside in DNA and RNA. Azacitidine and its deoxy derivative, decitabine (also known as 5-aza-2′-deoxycytidine) were first synthesized in Czechoslovakia as potential chemotherapeutic agents for cancer.
The most common adverse reactions in children with juvenile myelomonocytic leukemia include pyrexia, rash, upper respiratory tract infection, and anemia.
Excerpted from Wikipedia’s “azacitidine” article, available under the CC BY-SA 4.0 licence.